Quest Diagnostics plans to sell HemoCue diagnostic products business as part of its strategy to refocus on diagnostic information services
Quest Diagnostics Incorporated, the world's leading provider of diagnostic information services, today announced that it plans to sell its HemoCue diagnostic products business, as part of the company's strategy to refocus on diagnostic information services.
Quest Diagnostics agreed Friday to acquire Celera Corp. for about $344 million as the company seeks to expand in gene-based medical testing.